Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
NASDAQ:NKTR
Price:
1.32 USD
Market Closed
Updated:
Apr 29, 2024
Nektar Therapeutics
Cash from Investing Activities
|
Nektar Therapeutics
Cash from Investing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Cash from Investing Activities
$139.6m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Investing Activities
$878m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
40%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Investing Activities
-$32.3B
|
CAGR 3-Years
-96%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Investing Activities
-$14.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Investing Activities
-$7.2B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
See Also
What is Nektar Therapeutics's Cash from Investing Activities?
Cash from Investing Activities
139.6m
USD
139.6m
USD
Based on the financial report for Dec 31, 2023, Nektar Therapeutics's Cash from Investing Activities amounts to 139.6m USD.
What is Nektar Therapeutics's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
11%
11%
Over the last year, the Cash from Investing Activities growth was -62%. The average annual Cash from Investing Activities growth rates for Nektar Therapeutics have been -34% over the past three years , and 11% over the past ten years .
You don't have any saved screeners yet
